Health & Fitness

Expanded collaboration continues to leverage Congruence's proprietary computational drug discovery engine, Revenir™ to deliver Development Candidates in Neurology and ImmunologyCongruence...

- Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications...

Successfully started 216 patients on IBTROZI® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient...

NEWTON, Mass., March 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies,...

LAUSANNE, Switzerland, March 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the...

Prioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDETM) and Targeted Removal of Aberrant Protein (TRAPTM) extracellular...

FREDERICK, Md., March 2, 2026 /PRNewswire/ -- On Our Own of Frederick County announced today, that it has been approved for...

SEATTLE and MELBOURNE, Australia, March 2, 2026 /PRNewswire/ -- US BioTek Laboratories, a leading functional laboratory specializing in advanced immunological...

MAPLE GROVE, Minn., March 2, 2026 /PRNewswire/ -- Peli BioThermal, a global provider of temperature-controlled packaging solutions for the life sciences...

ALEXANDRIA, Va., March 2, 2026 /PRNewswire/ -- Prominently featured in The Inner Circle John P. Lynes, MD is honored as a...